| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 06/23/2004 | EP1429727A1 Apoptosis-mimicking synthetic entities and use thereof in medical treatment |
| 06/23/2004 | EP1429726A2 A method for preparing liposome formulations with a predefined release profile |
| 06/23/2004 | EP1429725A1 Ophthalmic depot formulations for periocular or subconjunctival administration |
| 06/23/2004 | EP1429724A1 Dosage form containing a confectionery composition |
| 06/23/2004 | EP1429723A1 Treating effects of excessive reactive oxygen species |
| 06/23/2004 | EP1429617A2 Methods for sterilizing preparations of digestive enzymes |
| 06/23/2004 | EP1429615A1 Oral vaccines |
| 06/23/2004 | EP1372392A4 Nicotine-containing oral dosage form |
| 06/23/2004 | EP1239832B1 Suspension comprising oxcarbazepine |
| 06/23/2004 | EP1206244B1 Aqueous pharmaceutical composition containing moxifloxacin or salts thereof |
| 06/23/2004 | EP1189620B1 Formulation comprising testosteron undecanoate and castor oil |
| 06/23/2004 | EP1071438B1 Stabilised herpesvirus preparation |
| 06/23/2004 | EP1063942B1 Liquid polymeric compositions for controlled release of bioactive substances |
| 06/23/2004 | EP0930886B1 Formulation for use in the prevention of pathogen induced diseases including hiv and hsv |
| 06/23/2004 | EP0850048B1 Pharmaceutical granules |
| 06/23/2004 | CN1507458A Water soluble, randomly substituted partial N-, partial O-acetylated chitosan, preserving compositions containing chitosan, and processes for making thereof |
| 06/23/2004 | CN1507358A Carrier with solid fibrinogen and solid thrombin |
| 06/23/2004 | CN1507357A Method and compositions for enhanced delivery of bioactive molecules |
| 06/23/2004 | CN1507347A Coated granules based on angiotensin-converting enzyme inhibitor |
| 06/23/2004 | CN1506350A Process for producing N-(4-fluobenzene radical)-N-(2-hydroxy-4-chlorobenzene group) glycocoll |
| 06/23/2004 | CN1506116A Process for preparing degradable polymer and medical composition containing the said polymer and use thereof |
| 06/23/2004 | CN1154659C Novel anti-AIDS immunotoxins |
| 06/23/2004 | CN1154512C Polymeric derivatives of camptothecins |
| 06/23/2004 | CN1154511C Oil-in-water emulsion exhibiting protective action against damages to human organs resultnig from peroxidation and prodn, and use thereof |
| 06/23/2004 | CN1154510C Preparation of directly mouldable tabletting auxiliary |
| 06/23/2004 | CN1154509C Multivalent vaccine compsn. with mixed carrier |
| 06/23/2004 | CN1154498C Process for preparation of oral pharmaceutical compositions comprising biphosphonates |
| 06/23/2004 | CN1154497C Method of treatment of lever tumours and pharmaceutical compositions for use therein |
| 06/23/2004 | CN1154482C Particles coated with granulated crystalline ibuprofen |
| 06/23/2004 | CN1154481C Taste masked pharmaceutical compositions |
| 06/23/2004 | CN1154479C Intraorally rapidly disintegrable tablet |
| 06/23/2004 | CN1154477C Pressurized metered dose inhalers and pharmaceutical aerosol formulations |
| 06/23/2004 | CN1154476C Improved fast disintegrating tablet |
| 06/22/2004 | US6753442 Amorphous nitric esters and their pharmaceutical compositions |
| 06/22/2004 | US6753423 For preferentially modulated gene expression in liver and associated tissues |
| 06/22/2004 | US6753330 2-benzyl-5-(4-chlorophenyl)-6-(4-(methylthio)phenyl)-2h -pyridazin-3-one, hydroxypropylmethylcellulose, and ethylene oxide-propylene oxide copolymer; interleukin inhibitors; rheumatic diseases |
| 06/22/2004 | US6753325 Comprises vitamin d3 for controlling cell differentiation and/or cell proliferation |
| 06/22/2004 | US6753313 Multimeric Apoa-I agonist compounds |
| 06/22/2004 | US6753165 Methods for making proteins containing free cysteine residues |
| 06/22/2004 | US6753017 Additional substance is added to the spray-drying process in a dry form during spray-drying to prepare dry extract from liquid extract |
| 06/22/2004 | US6753015 Microparticle compositions and methods for the manufacture thereof |
| 06/22/2004 | US6753014 Method to obtain microparticles |
| 06/22/2004 | US6753013 Vitamin d or vitamin d analogue; a corticosteroid; solvent; topical |
| 06/22/2004 | US6753008 Dietary supplements beneficial for the liver |
| 06/22/2004 | US6753006 Paclitaxel-containing formulations |
| 06/22/2004 | US6753005 Method for tissue perfusion |
| 06/22/2004 | US6752997 Process for preparing non-hygroscopic sodium valproate composition |
| 06/22/2004 | US6752942 Method of forming articles including waveguides via capillary micromolding and microtransfer molding |
| 06/22/2004 | CA2156075C Aerosol formulation containing a dispersing aid |
| 06/17/2004 | WO2004051263A1 Methods of measuring the dissolution rate of an analyte in a non-aqueous liquid composition |
| 06/17/2004 | WO2004050849A2 Recombinant immunotoxin and use in treating tumors |
| 06/17/2004 | WO2004050795A2 Antioxidant-functionalized polymers |
| 06/17/2004 | WO2004050712A1 Drug-sustained release carrier |
| 06/17/2004 | WO2004050710A2 Aldonic acid esters, methods for producing the same, and methods for producing pharmaceutical active ingredients coupled to polysaccharides or polysaccharide derivatives on free amino groups |
| 06/17/2004 | WO2004050707A2 Tumor-specific recognition molecules |
| 06/17/2004 | WO2004050698A2 Peptide conjugate useful for cell nucleus molecular imaging and tumor therapy |
| 06/17/2004 | WO2004050679A2 Mutant glycoproteins |
| 06/17/2004 | WO2004050123A2 Concentrated liquid valdecoxib composition |
| 06/17/2004 | WO2004050121A1 Pharmaceutical compositions of cell lysate and processes for the production and use thereof |
| 06/17/2004 | WO2004050113A1 TARGETED PROTEIN DEGRADATION VEHICLES (TPDVs), NUCLEIC ACID CONSTRUCTS ENCODING THEM AND THEIR USE |
| 06/17/2004 | WO2004050100A1 Method for treating a tumor using a thermo-gelling chitosan composition |
| 06/17/2004 | WO2004050098A1 Freeze-dried preparation of stabilized anthracycline compound |
| 06/17/2004 | WO2004050089A1 Epothilone analogs for site specific delivery in the treatment of proliferative diseases |
| 06/17/2004 | WO2004050083A1 Iontophoretic delivery of rotigotine for the treatment of parkinson's disease |
| 06/17/2004 | WO2004050072A1 Water-soluble composition containing coenzyme q10 |
| 06/17/2004 | WO2004050059A1 Low viscosity liquid dosage forms |
| 06/17/2004 | WO2004050057A2 An exopolysaccharides delivery system for active molecules |
| 06/17/2004 | WO2004050028A2 Density-controlled particulate suspensions for foodstuff, cosmetic, pharmaceutical and other uses |
| 06/17/2004 | WO2004050016A2 Delivery of pharmaceutical agents via the human insulin receptor |
| 06/17/2004 | WO2004050013A2 Material compositions and related systems and methods for treating cardiac conditions |
| 06/17/2004 | WO2004050012A2 Ifosfamide compositions for parenteral administration and a process for their preparation |
| 06/17/2004 | WO2004050011A2 High enantiomeric purity dexanabinol for pharmaceutical copositions |
| 06/17/2004 | WO2004049964A2 Drug to be introduced tooth or periodontal tissue and apparatus for introducing drug to tooth or periodontal tissue |
| 06/17/2004 | WO2004049917A2 Methods of therapy and diagnosis using targeting of cells that express ly-9 |
| 06/17/2004 | WO2004049907A2 Compositions and methods for treating transplants |
| 06/17/2004 | WO2004039360B1 Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
| 06/17/2004 | WO2004019870A3 Breath freshening and oral cleansing product using salicylaldehyde |
| 06/17/2004 | WO2004017907A3 Blood clot-targeted nanoparticles |
| 06/17/2004 | WO2004012651A3 Composition for heart disease, method to prepare same and uses thereof |
| 06/17/2004 | WO2004010941A3 Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
| 06/17/2004 | WO2004002404A3 Compositions and method for enhanced mucosal delivery of interferon beta |
| 06/17/2004 | WO2003105781A3 Ophthalmic compositions for treating ocular hypertension |
| 06/17/2004 | WO2003072047A3 Idothyronine compositions |
| 06/17/2004 | WO2003063824A3 Pharmaceutical composition |
| 06/17/2004 | WO2003028700A3 Water soluble nanoparticles of hydrophilic and hydrophobic active materials |
| 06/17/2004 | WO2002102309A3 Formulation of lymphokines and method of use thereof for local or bath local and systemic control of proliferative cell disorders |
| 06/17/2004 | WO2002076248A3 Customized therapeutics and in situ diagnostics |
| 06/17/2004 | US20040117033 Method for composite cell-based implants |
| 06/17/2004 | US20040116677 having a polymer backbone; a first pendent unit comprising a linking group connected to said polymer backbone and a saccharide moiety connected to said linking group |
| 06/17/2004 | US20040116673 Prodrugs; bone disorders |
| 06/17/2004 | US20040116652 Method for producing and using novel human defensins as biologically active proteins for treating infections and other diseases |
| 06/17/2004 | US20040116649 Polyoxyethylene glycol; purity, storage stability |
| 06/17/2004 | US20040116636 Methods and clinical devices for the inhibition or prevention of mammalian cell growth |
| 06/17/2004 | US20040116528 clear and stable solutions comprising alkali metal salts of 2-/3-benzoyl/phenylpropionic acidand optionally adjuvants, used as analgesics, antipyretics or antiinflammatory agents |
| 06/17/2004 | US20040116522 Medicinal solutions |
| 06/17/2004 | US20040116508 1-(N,N-bischloroethylaminoethoxy)-4-tert-butyldimethylsilyloxythioxanthone; administering first then sodium fluoride; tissue targeted therapy; administering in nontoxic, protodrug form which accumulates in neoplasm, followed by an activation drug |
| 06/17/2004 | US20040116419 Use of neuronal sodium channel antagonists for the control of ectoparasites in homeothermic animals |
| 06/17/2004 | US20040116352 Active substance combination containing a compound with an opioid effect and at least one further compound of formula 1 |
| 06/17/2004 | US20040116348 For selectively delivering drugs to target tissues |
| 06/17/2004 | US20040116345 Novel albumin-free factor VIII formulations |